Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer

被引：3
作者：
Reese, Adam C. [1 ]
Hardin, Jill [2 ,3 ]
Cheng, Iona [4 ]
Casey, Graham [5 ]
Witte, John S. [1 ,2 ,3 ]
机构：
[1] Univ Calif San Francisco, Dept Urol, 1450 3rd St, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Epidemiol & Biostat, San Francisco, CA 94158 USA
[3] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94158 USA
[4] Univ Hawaii, Canc Res Ctr Hawaii, Epidemiol Program, Honolulu, HI 96813 USA
[5] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90033 USA
来源：
PHARMACEUTICALS | 2010年 / 3卷 / 10期
基金：
美国国家卫生研究院;
关键词：
prostatic neoplasms; non-steroidal anti-inflammatory agents; aspirin; genetic variation; single nucleotide polymorphism;
D O I：
10.3390/ph3103127
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Increasing evidence suggests that prostatic inflammation plays a key role in the development of prostate cancer. It remains controversial whether non -steroidal antiinflammatory drugs (NSAIDs) reduce the risk of prostate cancer. Here, we investigate how a previously reported inverse association between NSAID use and the risk of aggressive prostate cancer is modulated by variants in several inflammatory genes. We found that NSAIDs may have differential effects on prostate cancer development, depending on one's genetic makeup. Further study of these inflammatory pathways may clarify the mechanisms through which NSAIDs impact prostate cancer risk.
引用
收藏
页码：3127 / 3142
页数：16
相关论文
共 63 条
  • [1] Effect of Aspirin, Other NSAIDs, and Statins on PSA and PSA Velocity
    Algotar, Amit M.
    Thompson, Patricia A.
    Ranger-Moore, James
    Stratton, M. Suzanne
    Hsu, Chiu-Hsieh
    Ahmann, Frederick R.
    Nagle, Raymond B.
    Stratton, Steven P.
    [J]. PROSTATE, 2010, 70 (08) : 883 - 888
  • [2] Celecoxib inhibits interleukin-12 αβ and β2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum
    Alloza, I
    Baxter, A
    Chen, Q
    Matthiesen, R
    Vandenbroeck, K
    [J]. MOLECULAR PHARMACOLOGY, 2006, 69 (05) : 1579 - 1587
  • [3] [Anonymous], 1988, NEW ENGL J MED, V318, P262
  • [4] Aspirin and the risk of prostate cancer
    Bosetti, C
    Talamini, R
    Negri, E
    Franceschi, S
    Montella, M
    La Vecchia, C
    [J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 2006, 15 (01) : 43 - 45
  • [5] Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer
    Chan, AT
    Giovannucci, EL
    Meyerhardt, JA
    Schernhammer, ES
    Curhan, GC
    Fuchs, CS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (08): : 914 - 923
  • [6] Chang SL, 2010, J CLIN ONCOL
  • [7] COX2 genetic variation, NSAIDs, and advanced prostate cancer risk
    Cheng, I.
    Liu, X.
    Plummer, S. J.
    Krumroy, L. M.
    Casey, G.
    Witte, J. S.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 97 (04) : 557 - 561
  • [8] Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence
    Cohen, Brian L.
    Gomez, Pablo
    Omori, Yohei
    Duncan, Robert C.
    Civantos, Francisco
    Soloway, Mark S.
    Lokeshwar, Vinata B.
    Lokeshwar, Bal L.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (05) : 1082 - 1087
  • [9] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [10] Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
    Cuzick, Jack
    Otto, Florian
    Baron, John A.
    Brown, Powel H.
    Burn, John
    Greenwald, Peter
    Jankowski, Janusz
    La Vecchia, Carlo
    Meyskens, Frank
    Senn, Hans Joerg
    Thun, Michael
    [J]. LANCET ONCOLOGY, 2009, 10 (05) : 501 - 507
1234567